stockrowZai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow ZLAB
Alert me
Zai Lab Limited Unsponsored ADR (ZLAB) Shares outstanding
Zai Lab Limited Unsponsored ADR's shares outstanding at the end of fiscal 2025 was $109.5M, up 10.7% from $98.9M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $111.7M. Over the past ten years it has ranged from $8.7M (fiscal 2015) to $109.5M (fiscal 2025) — the current reading is the highest in ten years. Zai Lab Limited Unsponsored ADR ranks 123rd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $109.5M | 10.70% |
| FY2024 | $98.9M | 2.39% |
| FY2023 | $96.6M | 0.87% |
| FY2022 | $95.8M | 3.03% |
| FY2021 | $93.0M | 19.73% |
| FY2020 | $77.7M | 20.66% |
| FY2019 | $64.4M | 22.35% |
| FY2018 | $52.6M | 141.85% |
| FY2017 | $21.8M | 130.46% |
| FY2016 | $9.4M | 8.57% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $111.7M | 0.87% |
| Mar 2026 | $110.7M | 1.10% |
| Dec 2025 | $109.5M | (0.61%) |
| Sep 2025 | $110.2M | 0.93% |
| 27 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RXRX Recursion Pharmaceuticals, Inc. compare | $543.0M |
| ADMA ADMA Biologics Inc compare | $225.8M |
| RCUS Arcus Biosciences, Inc. compare | $127.4M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $124.1M |
| ZLAB Zai Lab Limited Unsponsored ADR | $111.7M |
| CLDX Celldex Therapeutics, Inc. compare | $77.8M |
| XNCR Xencor, Inc. compare | $75.9M |
| PHVS Pharvaris N.V. compare | $68.1M |
| MBX MBX Biosciences, Inc. compare | $47.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ZLAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement